Kringle Pharma, Inc. Share Price

Equities

4884

JP3270790003

Biotechnology & Medical Research

Delayed Japan Exchange 11:30:00 26/06/2024 am IST 5-day change 1st Jan Change
1,028 JPY +2.39% Intraday chart for Kringle Pharma, Inc. +30.13% +36.70%

Financials

Sales 2022 391 62.49T 32.65T Sales 2023 69 11.03T 5.76T Capitalization 431.77Cr 69TCr 36TCr
Net income 2022 -33Cr -5.29TCr -2.76TCr Net income 2023 -85Cr -14TCr -7.13TCr EV / Sales 2022 -8,56,072 x
Net cash position 2022 275.6Cr 44TCr 23TCr Net cash position 2023 213.6Cr 34TCr 18TCr EV / Sales 2023 3,16,18,394 x
P/E ratio 2022
-6.6 x
P/E ratio 2023
-5.04 x
Employees 13
Yield 2022 *
-
Yield 2023
-
Free-Float 79.16%
More Fundamentals * Assessed data
Dynamic Chart
Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024 CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024 CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024 CI
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury CI
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries MT
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury CI
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury CI
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch) CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023 CI
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch) CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023 CI
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment MT
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury CI
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment MT
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury CI
More news
1 day+2.39%
1 week+30.13%
Current month+52.52%
1 month+60.62%
3 months+93.96%
6 months+43.58%
Current year+36.70%
More quotes
1 week
732.00
Extreme 732
1 067.00
1 month
615.00
Extreme 615
1 067.00
Current year
394.00
Extreme 394
1 067.00
1 year
394.00
Extreme 394
1 067.00
3 years
394.00
Extreme 394
1 404.00
5 years
394.00
Extreme 394
1 780.00
10 years
394.00
Extreme 394
1 780.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 01/04/01
Chief Administrative Officer 55 01/17/01
Director/Board Member 72 01/16/01
Members of the board TitleAgeSince
Director/Board Member 75 01/18/01
Chief Executive Officer 57 01/04/01
Director/Board Member 53 01/16/01
More insiders
Date Price Change Volume
26/24/26 1,028 +2.39% 986 800
25/24/25 1,004 +6.13% 1,210,300
24/24/24 946 +18.84% 1,051,200
21/24/21 796 -1.24% 195,100
20/24/20 806 +2.03% 569,500

Delayed Quote Japan Exchange, June 26, 2024 at 11:30 am IST

More quotes
Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.
More about the company